Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.63 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | RELA | Q04206 | 3/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.63 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.63 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.61 |
| ▸ | VCP | P55072 | 1/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MBD2 | Q9UBB5 | 2/20 | 0.53 |
| ▸ | KCNN1 | Q92952 | 2/20 | 0.53 |
| ▸ | KCNN2 | Q9H2S1 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206699 | 1.00 | MAPT (0.63) | MAPTSMN1; SMN2NFKB1NFKB2KMT2A | |
| SCHEMBL206530 | 0.91 | MAPT (0.52) | MAPTSMN1; SMN2NFKB1NFKB2KMT2A | |
| SCHEMBL206487 | 0.91 | MAPT (0.52) | MAPTSMN1; SMN2NFKB1NFKB2KMT2A | |
| SCHEMBL6368696 | 0.86 | SLC2A1 (0.64) | MAPTSMN1; SMN2NFKB1NFKB2KMT2A | |
| SCHEMBL205469 | 0.85 | MAPT (0.62) | MAPTSMN1; SMN2NFKB1NFKB2KMT2A | |
| SCHEMBL206048 | 0.85 | MAPT (0.62) | MAPTSMN1; SMN2NFKB1NFKB2KMT2A | |
| Hydrochloric Acid SCHEMBL5172910 | 0.85 | SLC2A1 (0.62) | MAPTSMN1; SMN2NFKB1NFKB2KMT2A | |
| SCHEMBL205525 | 0.80 | MEN1 (0.65) | MAPTSMN1; SMN2KMT2AMEN1VCP | |
| SCHEMBL207008 | 0.80 | MEN1 (0.65) | MAPTSMN1; SMN2KMT2AMEN1VCP | |
| SCHEMBL206136 | 0.80 | MEN1 (0.65) | MAPTSMN1; SMN2KMT2AMEN1VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | claimed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | MAPT 2207/4885SMN1; SMN2 3252/4885NFKB1 3007/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | MAPT 2207/4885SMN1; SMN2 3252/4885NFKB1 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.